Anatabine lowers Alzheimer's Aβ production in vitro and in vivo
Bibliographic
Year of Publication:
2011
Contact PI Name:
Daniel Paris
Primary Reference (PubMED ID):
Funding Source:
Not Reported
Study Goal and Principal Findings:
Antabine is a minor tobacco alkaloid which is present in plants of the Solanacea family including tobacco, green tomatoes, peppers and eggplants. In the present study the authors investigated the effects of anatabine on Aβ production in vitro and in vivo in a transgenic mouse model of Alzheimer's disease. Data show that anatabine inhibits NFκB activation, inhibits BACE-1 transcription and reduces BACE-1 protein levels, and significantly lowers brain soluble Aβ1–40 and Aβ1–42 levels in a transgenic mouse model of Alzheimer's disease. The data suggest that anatabine may be a useful compound for regulating brain Aβ accumulation.
Therapeutic Agent
Therapeutic Information:
Therapy Type:
Natural Product
Therapeutic Agent:
Anatabine
Therapeutic Target:
Multi Target
Animal Model
Model Information:
Species:
Mouse
Model Type:
Non-transgenic
Strain/Genetic Background:
C57Bl6/SJL
Species:
Mouse
Model Type:
APPxPS1
Model Name:
PS/APP
Strain/Genetic Background:
Not Reported
Experimental Design
Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest
Outcomes
Outcome Measured
Outcome Parameters
Biochemical
Brain-beta Amyloid Peptide 40
Brain-beta Amyloid Peptide 42
Plasma-beta Amyloid Peptide 40
Plasma-beta Amyloid Peptide 42
C-Reactive Protein (CRP)
Nuclear Factor kappa B (NFkB)
Soluble Amyloid Precursor Protein alpha (sAPP alpha)
Soluble Amyloid Precursor Protein beta (sAPP beta)
beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1)
Biomarker
Plasma-beta Amyloid Peptides
Pharmacokinetics
Drug Concentration-Plasma
Drug Concentration-Brain
Cmax
Area Under the Curve (AUC)